We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
Domo
DOMO
$179M
| $482K | ﹤0.01% |
22,205
+188
| +0.9% | +$3.47K |
|
2377
Voyager Therapeutics
VYGR
$187M
| $482K | ﹤0.01% |
34,581
+2,151
| +7% | +$31.3K |
|
|
SMMF
2378
DELISTED
Summit Financial Group, Inc.
SMMF
| $482K | ﹤0.01% |
17,777
+340
| +2% | +$8.96K |
|
2379
Artesian Resources
ARTNA
$352M
| $480K | ﹤0.01% |
12,892
-88
| -0.7% | -$3.26K |
|
2380
Gogo Inc
GOGO
$603M
| $478K | ﹤0.01% |
74,664
+463
| +0.6% | +$2.69K |
|
2381
Precision BioSciences
DTIL
$193M
| $476K | ﹤0.01% |
+1,143
| New | +$359K |
|
|
BVH
2382
DELISTED
Bluegreen Vacations Holding Corporation
BVH
| $476K | ﹤0.01% |
19,975
+90
| +0.5% | +$2.07K |
|
2383
Greif Class B
GEF.B
$4.23B
| $475K | ﹤0.01% |
9,176
+82
| +0.9% | +$4.07K |
|
2384
Energy Recovery
ERII
$457M
| $474K | ﹤0.01% |
48,386
+321
| +0.7% | +$2.96K |
|
|
CPRX
2385
DELISTED
Catalyst Pharmaceutical
CPRX
| $473K | ﹤0.01% |
126,145
+753
| +0.6% | +$3.52K |
|
2386
Farmers & Merchants Bancorp
FMAO
$470M
| $473K | ﹤0.01% |
15,672
+69
| +0.4% | +$1.83K |
|
2387
Hooker Furnishings Corp
HOFT
$159M
| $471K | ﹤0.01% |
18,323
+72
| +0.4% | +$1.69K |
|
2388
Magnite
MGNI
$2.96B
| $470K | ﹤0.01% |
57,611
+1,032
| +2% | +$8.48K |
|
2389
Adaptive Biotechnologies
ADPT
$3.91B
| $469K | ﹤0.01% |
15,660
+4,291
| +38% | +$123K |
|
2390
Lifecore Biomedical
LFCR
$167M
| $469K | ﹤0.01% |
41,485
+82
| +0.2% | +$873 |
|
2391
National Bankshares
NKSH
$262M
| $469K | ﹤0.01% |
10,430
-8
| -0.1% | -$343 |
|
|
ZIXI
2392
DELISTED
Zix Corporation
ZIXI
| $469K | ﹤0.01% |
69,161
+242
| +0.4% | +$1.67K |
|
|
BHR
2393
Braemar Hotels & Resorts
BHR
$141M
| $468K | ﹤0.01% |
52,401
-527
| -1% | -$4.93K |
|
2394
Lennar Class B
LEN.B
$20.8B
| $467K | ﹤0.01% |
10,996
+502
| +5% | +$22.3K |
|
2395
Southern First Bancshares
SFST
$608M
| $467K | ﹤0.01% |
10,986
+53
| +0.5% | +$2.21K |
|
2396
NVE Corp
NVEC
$613M
| $466K | ﹤0.01% |
6,523
+122
| +2% | +$7.95K |
|
|
MCBC
2397
DELISTED
Macatawa Bank Corp
MCBC
| $466K | ﹤0.01% |
41,877
-186
| -0.4% | -$1.98K |
|
2398
Vanguard Total Bond Market
BND
$158B
| $464K | ﹤0.01% |
5,532
| – | – |
|
|
DSSI
2399
DELISTED
Diamond S Shipping Inc. Common Shares
DSSI
| $464K | ﹤0.01% |
27,703
+1,763
| +7% | +$26.4K |
|
|
SCTL
2400
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $463K | ﹤0.01% |
25,235
-2,540
| -9% | -$36.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.